InsiderTrades

Form 4 for ABT Abbott Laboratories

Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-17 · accession 0001415889-23-003056 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-02-22 2023-02-19+ ABT Mateus Fernando SVP F - Tax $106.74 -1,182 24.5K -5% -$126.2K
D 2023-02-22 2023-02-17 ABT Mateus Fernando SVP A - Grant $0.00 +10.6K 25.1K +73% $0
D 2023-02-22 2023-02-17 ABT Mateus Fernando SVP A - Grant $0.00 +41.6K 41.6K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common shares without par value 2023-02-21 F D 664 $106.74 23,881 D — —
2 Common Common shares without par value 2023-02-19 F D 518 $106.74 24,545 D — —
3 Common Common shares without par value 2023-02-17 A A 10,560 $0.00 25,063 D — — (F1) These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
4 Derivative Option (right to buy) 2023-02-17 A A 41,648 $0.00 41,648 D $106.24 · 2024-02-17 to 2033-02-16 41,648 Common Shares (F2) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,882 on February 17, 2024, 13,883 on February 17, 2025, and 13,883 on February 17, 2026.